The FDA on May 27, 2022, granted accelerated approval to KYMRIAH® (Tisagenlecleucel) for adult patients with Relapsed or Refractory Follicular Lymphoma (FL), after two or more lines of systemic therapy. KYMRIAH® is a product of Novartis Pharmaceuticals Corporation.
Other Pages – Bottom Ad
Advertisement
Subscribe
